PMID- 30222190
OWN - NLM
STAT- MEDLINE
DCOM- 20190205
LR  - 20190215
IS  - 1098-2299 (Electronic)
IS  - 0272-4391 (Linking)
VI  - 79
IP  - 6
DP  - 2018 Sep
TI  - Neuroprotection of rhGLP-1 in diabetic rats with cerebral ischemia/reperfusion 
      injury via regulation of oxidative stress, EAAT2, and apoptosis.
PG  - 249-259
LID - 10.1002/ddr.21439 [doi]
AB  - Preclinical Research & Development The purpose of the present study is to 
      evaluate the neuroprotective effect of recombinant human glucagon-like peptide-1 
      (rhGLP-1) as well as to explore corresponding mechanisms in diabetic rats with 
      cerebral ischemia/reperfusion injury induced by middle cerebral artery occlusion 
      (MCAO). Diabetes mellitus was induced by intraperitoneal injection of 
      streptozotocin. The rats were pretreated with rhGLP-1 (20 mug/kg 
      intraperitoneally, thrice a day) for 14 days. Thereafter, the rats were subjected 
      to MCAO 90 min/reperfusion 24 hr. At 2 and 24 hr of reperfusion, the rats were 
      assessed for neurological deficits and subsequently executed for the evaluation 
      of cerebral infarct volume, oxidative stress parameters, and the expression of 
      excitatory amino acid transporter 2 (EAAT2) and apoptotic markers. Results 
      indicate that rhGLP-1 significantly ameliorated neurological deficits and reduced 
      cerebral infarct volume in diabetic MCAO rats. In addition, oxidative stress 
      parameters in ischemic penumbra were significantly alleviated in 
      rhGLP-1-pretreated diabetic MCAO rats. rhGLP-1 significantly upregulated the 
      ratio of Bcl-2/Bax and EAAT2 expression and downregulated cleaved caspase-3 
      expression in ischemic penumbra of diabetic MCAO rats. Our results suggest that 
      rhGLP-1 could significantly ameliorate neurological deficits and reduce cerebral 
      infarct volume in diabetic MCAO rats, which may be due to the inhibition of 
      oxidative stress and apoptosis and the promotion of EAAT2 expression.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Fang, Yi
AU  - Fang Y
AD  - Department of Pharmacy, Peking University People's Hospital, Beijing, People's 
      Republic of China.
FAU - Jiang, Daoli
AU  - Jiang D
AUID- ORCID: 0000-0002-5566-6585
AD  - Department of Pharmacy, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, People's Republic of China.
FAU - Wang, Yitong
AU  - Wang Y
AD  - Department of Pharmacy, Peking University People's Hospital, Beijing, People's 
      Republic of China.
AD  - Department of Pharmacy Administration and Clinical Pharmacy, Peking University 
      Health Science Center, Beijing, People's Republic of China.
FAU - Wang, Qian
AU  - Wang Q
AD  - Department of Pharmacy, Peking University People's Hospital, Beijing, People's 
      Republic of China.
FAU - Lv, Dongmei
AU  - Lv D
AD  - Department of Pharmacy, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, People's Republic of China.
FAU - Liu, Jichao
AU  - Liu J
AD  - Animal Experimental Center, Peking University People's Hospital, Beijing, 
      People's Republic of China.
FAU - Liu, Chang
AU  - Liu C
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, People's Republic of China.
LA  - eng
GR  - No: 2013-22/Peking University People's Hospital Research and Development 
      Funds/International
GR  - Peking University/International
GR  - Research and Development/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180917
PL  - United States
TA  - Drug Dev Res
JT  - Drug development research
JID - 8204468
RN  - 0 (Excitatory Amino Acid Transporter 2)
RN  - 0 (Incretins)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Slc1a2 protein, rat)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Brain Ischemia/complications/*drug therapy
MH  - Diabetes Complications/drug therapy/physiopathology
MH  - Diabetes Mellitus/*drug therapy/physiopathology
MH  - Excitatory Amino Acid Transporter 2/metabolism
MH  - Glucagon-Like Peptide 1/*genetics/*pharmacology
MH  - Humans
MH  - Incretins/*pharmacology
MH  - Infarction, Middle Cerebral Artery
MH  - Neuroprotective Agents
MH  - Oxidative Stress/drug effects
MH  - Rats
MH  - Recombinant Proteins/*pharmacology
MH  - Reperfusion Injury/complications/drug therapy/physiopathology
OTO - NOTNLM
OT  - cerebral ischemia/reperfusion injury
OT  - diabetes
OT  - rhGLP-1
EDAT- 2018/09/18 06:00
MHDA- 2019/02/06 06:00
CRDT- 2018/09/18 06:00
PHST- 2018/01/30 00:00 [received]
PHST- 2018/06/05 00:00 [revised]
PHST- 2018/06/07 00:00 [accepted]
PHST- 2018/09/18 06:00 [pubmed]
PHST- 2019/02/06 06:00 [medline]
PHST- 2018/09/18 06:00 [entrez]
AID - 10.1002/ddr.21439 [doi]
PST - ppublish
SO  - Drug Dev Res. 2018 Sep;79(6):249-259. doi: 10.1002/ddr.21439. Epub 2018 Sep 17.